Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.

By J. Sackner-Bernstein, M. Kowalski, Marshal T. Fox, Keith D. Aaronson. Journal of the American Medical Association (JAMA), 2005

638 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology

View Paper: https://www.semanticscholar.org/paper/1fbc3dbdc116c255334bb5a9982950bfb6ba13ac

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Gheorghiade
2. G. Fonarow
3. J. Januzzi
4. T. Horwich
5. Robert M. Califf
6. J. Udelson
7. C. Yancy
8. M. Drazner

In Hematology

1. M. Gheorghiade

Citations in the corpus

• Acute heart failure syndromes (2009, background): “IV inotropes and vasodilators that nitially improve signs and symptoms may adversely affect ost-discharge outcomes (39,41,42,71,109,110).”
• Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1) (2013, background): “Sackner-Bernstein and colleagues analyzed mortality data from 12 randomized trials; three trials provided 30-day mortality data, and found a trend towards an increased risk of death in nesiritide-treated subjects [86].”
• Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (2007, background): “Metaanalyses have suggested an association between nesiritide use and an increased risk for renal dysfunction(29) and 30-day mortality.(30,31) Levosimendan, a calcium-sensitizer, is in clinical use in several countries in Europe, South America, and Asia.”
• Natriuretic Peptides: Their Structures, Receptors, Physiologic Functions and Therapeutic Applications (2009, result): “…not improve renal function in patients with chronic heart failure (Wang et al. 2004), but more damaging were two meta-analysis studies by Sackner-Bernstein and colleagues indicating that nesiritide worsened renal function and increased the likelihood of death (Sackner-Bernstein et al. 2005a, b).”
• Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. (2007, background): “Vital signs, mean (SD) Systolic BP, mm Hg 116 (18) 116 (19)”
• Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. (2005, background): “tality in the advanced heart failure population.(26,27) In addition, there is little”
• Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. (2007, background): “concern has been raised about the adverse effect of these treatments on long-term clinical outcomes.(10-17) Volume overload remains a major cause of hospitalization and of continued morbidity among hospitalized patients,(18,19) and concern exists regarding the adverse renal impact of diuretic and ot”
• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, methodology): “In all patients with a recent or remote history of MI or ACS and reduced EF, evidence-based beta blockers should be used to reduce mortality (346-348).”